Yuying Kou

Yuying Kou

Auto-generated profile, based on publicly available information

Yuying Kou

School of Stomatology, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, People’s Republic of China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2022 in ACS Omega
Verified
Journal Article
Open access
QZQin Zhou
Qin Zhou
SLShanshan Liu
Shanshan Liu
YKYuying Kou
Yuying Kou
PYPanpan Yang
Panpan Yang
HLHongrui Liu
Hongrui Liu
Minqi LiMinqi Li
Minqi Li
Oral cancer is one of the most common malignancies of the head and neck, and approximately 90% of oral cancers are oral squamous cell carcinomas (OSCCs). The purinergic P2Y2 receptor is upregulated in breast cancer, pancreatic cancer, colorectal cancer, and liver cancer, but its role in OSCC is still unclear. Here, we examined the effects of P2Y2 on the invasion and migration of oral cancer cells (SCC15 and CAL27). The BALB/c mouse model was used to observe the involvement of P2Y2 with tumors in vivo. P2Y2, Src, and EGFR are highly expressed in OSCC tissues and cell lines. Stimulation with ATP significantly enhanced cell invasion and migration in oral cancer cells, and enhanced the activity of Src and EGFR protein kinases, which is mediated by the PI3K/AKT signaling pathway. P2Y2 knockdown attenuated the above ATP-driven events in vitro and in vivo. The PI3K/ AKT signaling pathway was blocked by Src or EGFR inhibitor. Extracellular ATP activates the PI3K/AKT pathway through the P2Y2-Src-EGFR axis to promote OSCC invasion and migration, and thus, P2Y2 may be a potential novel target for antimetastasis therapy.

1 May 2024 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
KWKe Wang
Ke Wang
YKYuying Kou
Yuying Kou
XRXing Rong
Xing Rong
LWLingling Wei
Lingling Wei
JLJingyuan Li
Jingyuan Li
HSHui Song
Hui Song
Purpose: Estrogen deficiency is the main reason of postmenopausal osteoporosis. Eldecalcitol (ED-71) is a new active vitamin D analogue clinically used in the treatment of postmenopausal osteoporosis. We aimed to investigate whether EphrinB2-EphB4 and RANKL/RANK/OPG signaling cooperate in mediating the process of osteoporosis by ED-71. Methods: In vivo, the ovariectomized (OVX) rats were administered orally with 30 ng/kg ED-71 once a day for 8 weeks. HE staining, Masson staining and Immunofluorescence staining were used to evaluate bone mass, bone formation, osteoclastogenesis associated factors and the expression of EphrinB2, EphB4, RANKL and OPG. In vitro, H2O2 stimulation was used to simulate the cell environment in osteoporosis. Immunofluorescence, quantitative real time PCR (qRT-PCR), enzyme-linked immunosorbent assay (ELISA) and Western Blot were applied to detect the expression of EphrinB2, EphB4, RANKL and OPG. In osteoblasts, EphB4 was knocked down by EphB4 small-interfering RNA (siRNA) transfection. LY294002 (PI3K inhibitor) or ARQ092 (AKT inhibitor) was used to block PI3K/AKT pathway. An indirect co-culture system of osteoblasts and osteoclasts was established. The mRNA and protein expression of osteoclastogenes is associated factors were tested by qRT-PCR and Western Blot. Results: ED-71 increased bone mass and decreased the number of osteoclasts in OVX rats. Moreover, ED-71 promoted the expression of EphrinB2, EphB4, and decreased the RANKL/OPG ratio in osteoblasts. Osteoclastogenesis was restrained when osteoclasts were indirectly co-cultured with ED-71-treated osteoblasts. After silencing of EphB4 expression in osteoblasts, ED-71 inhibited the expression of P-PI3K and P-AKT and increased the ratio of RANKL/OPG. This reversed the inhibitory effect of ED-71 on osteoclastogenes. Therefore, in ED-71-inhibited osteoclastogenes, EphB4 is a key factor affecting the secretion of RANKL and OPG by osteoblasts. EphB4 suppressed the RANKL/OPG ratio through activating PI3K/AKT signaling in osteoblasts. Conclusion: ED-71 inhibits osteoclastogenesis through EphrinB2-EphB4-RANKL/OPG axis, improving bone mass in ovariectomized rats. PI3K/AKT pathway is involved this process.

22 March 2022 in Oral Diseases
Verified
Journal Article
Closed access
YJYujun Jiang
Yujun Jiang
PYPanpan Yang
Panpan Yang
CLCongshan Li
Congshan Li
YLYupu Lu
Yupu Lu
YKYuying Kou
Yuying Kou
Minqi LiMinqi Li
Minqi Li

5 November 2021 in Oral Diseases
Verified
Journal Article
Closed access
PDF file
YKYuying Kou
Yuying Kou
YJYujun Jiang
Yujun Jiang
SLShanshan Liu
Shanshan Liu
PYPanpan Yang
Panpan Yang
YLYupu Lu
Yupu Lu
Minqi LiMinqi Li
Minqi Li

24 August 2021 in Oral Diseases
Verified
Journal Article
Closed access
PDF file
YLYupu Lu
Yupu Lu
YKYuying Kou
Yuying Kou
YGYuan Gao
Yuan Gao
PYPanpan Yang
Panpan Yang
SLShanshan Liu
Shanshan Liu
Minqi LiMinqi Li
Minqi Li

1 December 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
ZZZhichao Zhang
Zhichao Zhang
XRXing Rong
Xing Rong
QRQinghua Ren
Qinghua Ren
YKYuying Kou
Yuying Kou
JGJie Guo
Jie Guo
Minqi LiMinqi Li
Minqi Li
Purpose: Glucocorticoid-induced osteoporosis (GIOP) is the most common form of secondary osteoporosis, and its pathogenesis is closely associated with oxidative stress and impaired osteogenic differentiation. Vitamin K2 (VK2) has strong antioxidant properties and potent bone-forming effects, but its application in GIOP is still unclear. This study investigates the therapeutic potential of VK2 in GIOP and elucidates its underlying molecular mechanisms. Methods: Dexamethasone (DEX) was used to establish GIOP model within C57BL/6 mice. The bone mass was assessed using micro-computed tomography (micro-CT), hematoxylin and eosin (HE) staining, and Masson’s trichrome staining in vivo. The osteoblast activity and the expression of osteogenic and ferroptosis-related markers were evaluated via immunohistochemistry (IHC), RT-qPCR, Western blotting, ALP and alizarin red staining. The mitochondrial function and lipid peroxidation of MC3T3-E1 cells were detected by flow cytometry, immunofluorescence and specific kits. Results: VK2 partially prevented bone mass reduction and osteoblast activity inhibition in GIOP mice. VK2 not only reversed the DEX-induced reductions in Tb.N, BV/TV, and Tb.Th, but also significantly increased the expression of osteogenic markers, including OCN and ALP (P< 0.05). Moreover, VK2 improved DEX-induced ferroptosis, oxidative stress and mitochondrial dysfunction in MC3T3-E1 cells and promoted osteogenic differentiation in vitro, which could be reversed by ferroptosis inducer (P< 0.05). VK2 also increased the expression of NRF2, HO-1 and FSP1 which inhibited by DEX in vivo and in vitro (P< 0.05). The inhibition of FSP1 and NRF2 reversed the osteogenic differentiation promotion and ferroptosis inhibition by VK2 (P< 0.05). Conclusion: VK2 restores mitochondrial function and reduces lipid peroxidation and ferroptosis via the NRF2/FSP1 signaling pathway, thereby facilitating osteoblast differentiation and improving bone mass in GIOP mice. This finding not only provides a fresh perspective on the etiology of GIOP but also positions ferroptosis inhibition as a promising and innovative therapeutic strategy for this condition, with VK2 emerging as a potential candidate for clinical translation.